Nobiletin Inhibits Epithelial-Mesenchymal Transition Of Human Non-Small Cell Lung Cancer Cells By Antagonizing The Tgf-Beta 1/Smad3 Signaling Pathway

Epithelial-mesenchymal transition (EMT) is a critical cellular process in cancer metastasis, during which epithelial polarized cells become motile mesenchymal cells. Since transforming growth factor-beta (TGF-beta) is a potent inducer of EMT, blocking of TGF-beta/Smad signaling has become a promising cancer therapy. Nobiletin, a polymethoxy flavonoid from Citrus depressa, has been shown to be valuable for cancer treatment, yet the mechanism remains unclear. In the present study, lung adenocarcinoma A549 and H1299 cells were used to evaluate the effect of nobiletin on EMT induced by TGF-beta 1. Nobiletin successfully inhibited TGF-f31-induced EMT, migration, invasion and adhesion in vitro, accompanied by attenuation of MMP-2, MMP-9, p-Src, p-FAK, p-paxillin, Snail, Slug, Twist and ZEB1 expression. Nobiletin inhibited the transcriptional activity of Smads without changing the phosphorylation status or translocation of Smads induced by TGF-beta 1. Moreover, Smad3 is requisite in TGF-beta 1-stimulated EMT. Smad3 overexpression meaningfully impaired the ability of nobiletin to reverse TGF-beta 1-induced EMT. In vivo, nobiletin prohibited the growth of metastatic nodules in the lungs of nude mice. Moreover, nobiletin inhibited tumor growth and reversed EMT in mice bearing A549-Luc xenografts, as revealed by IVIS imaging and immunohistochemical analysis. Collectively, the data suggest that nobiletin prevents EMT by inactivating TGF-beta 1/Smad3 signaling.